atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

2d ago

ATAI

PremiumPress Releases

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

9d ago

ATAI

PremiumPress Releases

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

29d ago

ATAI

PremiumPress Releases

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

30d ago

ATAI

PremiumPre-Earnings

Atai Life Sciences N.V. (ATAI) Q4 Earnings Cheat Sheet

1M ago

ATAI

PremiumPress Releases

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

2M ago

ATAI

PremiumPress Releases

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

2M ago

ATAI

More ATAI News >

ATAI News on the Web

2024-04-24

atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resist

Proactive Investors

Neutral

2024-04-24

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Yahoo Finance

Neutral

2024-04-23

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week

TalkMarkets

Neutral

2024-04-17

atai hails publication of Beckley Psytech's Phase 1 study of DMT treatment

Proactive Investors

Neutral

2024-04-17

atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT asset

Proactive Investors

Neutral

2024-04-17

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Yahoo Finance

Neutral

2024-04-15

atai Life Sciences CEO spotlights psychedelic therapy milestones and upcoming catalysts

Proactive Investors

Neutral

2024-04-15

atai Life Sciences CEO spotlights psychedelic therapy milestones and upcoming catalysts

Proactive Investors

Neutral

News Score - Last 7 Days

Neutral

ATAI

Sector Average

Media Buzz

This Week3 articles

Weekly Average4 articles

News Sentiment

This Week50%

Sector Average58%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ATAI’s Media Buzz Sentiment?

3 articles about ATAI were published this week. In an average week, 4 articles are published.

What is ATAI’s weekly average amount of articles?

In an average week, 4 articles about ATAI are published.

What is ATAI’s News Sentiment?

50% of articles about ATAI were positive this week, compared to its sector average of 58%.

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

TAKTakeda Pharmaceutical Company

NBIXNeurocrine

AMEDAmedisys

MORFMorphic Holding

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing